PF-03715455

• Description:

  PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM) . PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) [1][2].

• UNSPSC:

  12352005

• Target:

  P38 MAPK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pf-03715455.html

• Purity:

  98.44

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C1=NN(C2=CC=C(O)C(Cl)=C2)C(NC(NCC3=CC=CC=C3SC4=CN5C(C6=CC=CC=C6SCCO)=NN=C5C=C4)=O)=C1)C

• Molecular Formula:

  C35H34ClN7O3S2

• Molecular Weight:

  700.27

• References & Citations:

  [1]Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24 (3) :383-92.|[2]Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54 (22) :7797-814.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  P38α; p38β

• CAS Number:

  [1056164-52-3]